Mint Pharmaceuticals Inc. is recalling all lots of its prescription losartan ... HCTZ 50/12.5 mg TABLETS Mint Pharmaceuticals Inc. 02389657 2005011156 June 2023 MINT-LOSARTAN/HCTZ 100/12.5 mg ...

The recalled 100 mg/25 mg losartan and potassium/hydrochlorothiazide tablets contained small amounts of N-nitrosodiethylamine, or NDEA, according to a company recall notice shared on the Food and ...

Losartan tablets have been approved in 25-mg, 50-mg, and 100-mg doses, and losartan/hydrochlorothiazide combination tablets will be available in 50-mg/12.5-mg, 100-mg/12.5-mg, and 100-mg/25-mg ...

This covers lot No. JB8912 of Losartan Potassium Hydrochlorothiazide 100 mg or 25 mg tablets in 1,000-count bottles, expiration date 06/2020. None of the recalled tablets were distributed before ...

Macleods Pharmaceuticals is recalling 32 lots of losartan potassium USP tablets and losartan potassium/hydrochlorothiazide (HCTZ) combination tablets after discovering trace amounts of the ...

and hydrochlorothiazide 12.5 mg (H12.5), a thiazide diuretic, was approved as PREMINENT LD (Merck, Whitehouse Station, NJ, USA) in Japan in 2006. The higher-dose combination of losartan 100 mg ...

For patients titrated to losartan 100 mg/HCTZ 25 mg at week 12, an optional visit at week 16 was permitted to assess whether addition of a CCB is required to reach BP goals. Written informed ...

Losartan potassium ... used losartan potassium tablets sold nationwide after finding trace amounts of a probable carcinogen. The recall involves losartan and potassium/hydrochlorothiazide ...

Additionally, the company received tentative approval for the 50 mg/12.5 mg and 100 mg/25 mg strengths ... 180-day exclusivity period. Losartan Potassium and HCTZ Tablets had U.S. sales of ...